We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
Read MoreHide Full Article
Alkermes plc (ALKS - Free Report) announced the initiation of a new phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
The company’s shares have declined 10% so far this year against the industry’s growth of 2.7%.
ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. The selectivity of ALKS 4230 is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
The ARTISTRY-3 study will evaluate treatment-emergent changes in the tumor microenvironment and peripheral blood immunophenotypes, as well as the safety, tolerability, and pharmacokinetic profile of ALKS 4230 (6µg/kg) dosed intravenously, as lead-in monotherapy, followed by combination with Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with select advanced malignant solid tumors. The study will also assess clinical anti-tumor activity (overall response rate and duration of response) of ALKS 4230 as one of its secondary objectives.
Early clinical data from the ARTISTRY program showed that ALKS 4230 selectively expanded cancer-fighting immune cells in the periphery, with negligible effects on regulatory T cells.
ARTISTRY-3 is the fourth study evaluating ALKS 4230 as a novel immuno-oncology candidate.
ALKS 4230 is being evaluated under the ARTISTRY clinical development program in patients with advanced solid tumors. The company is developing the candidate in three distinct stages under ARTISTRY-1, an ongoing phase I/II study of ALKS 4230 administered via intravenous infusion as a monotherapy and in combination with the Keytruda. Itis designed to evaluate the safety profile and anti-tumor activity of ALKS 4230 in patients with select advanced solid tumors. ARTISTRY-2is an ongoing phase I/II study,in which ALKS 4230 is administered subcutaneously as monotherapy and in combination with Keytruda in patients with advanced solid tumors.
Zacks Rank and Stocks to Consider
Currently, Alkermes is a Zacks Rank #3 (Hold) stock.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
Alkermes plc (ALKS - Free Report) announced the initiation of a new phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
The company’s shares have declined 10% so far this year against the industry’s growth of 2.7%.
ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. The selectivity of ALKS 4230 is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
The ARTISTRY-3 study will evaluate treatment-emergent changes in the tumor microenvironment and peripheral blood immunophenotypes, as well as the safety, tolerability, and pharmacokinetic profile of ALKS 4230 (6µg/kg) dosed intravenously, as lead-in monotherapy, followed by combination with Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with select advanced malignant solid tumors. The study will also assess clinical anti-tumor activity (overall response rate and duration of response) of ALKS 4230 as one of its secondary objectives.
Early clinical data from the ARTISTRY program showed that ALKS 4230 selectively expanded cancer-fighting immune cells in the periphery, with negligible effects on regulatory T cells.
ARTISTRY-3 is the fourth study evaluating ALKS 4230 as a novel immuno-oncology candidate.
ALKS 4230 is being evaluated under the ARTISTRY clinical development program in patients with advanced solid tumors. The company is developing the candidate in three distinct stages under ARTISTRY-1, an ongoing phase I/II study of ALKS 4230 administered via intravenous infusion as a monotherapy and in combination with the Keytruda. Itis designed to evaluate the safety profile and anti-tumor activity of ALKS 4230 in patients with select advanced solid tumors. ARTISTRY-2is an ongoing phase I/II study,in which ALKS 4230 is administered subcutaneously as monotherapy and in combination with Keytruda in patients with advanced solid tumors.
Zacks Rank and Stocks to Consider
Currently, Alkermes is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) and Horizon Therapeutics Public Limited Company , both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.45 to $5.60 for 2020 and from $3.73 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.86 for 2020 and from $2.72 to $4.29 for 2021 over the past 60 days.
Alkermes plc Price
Alkermes plc price | Alkermes plc Quote
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>